Olanzapine
DrugTarget oral dose of 20 milligrams per day for 6 months
NCT Number: NCT00236379
The purpose of this study is to assess and compare how risperidone and olanzapine, two antipsychotic medications, affect the regulation of glucose (sugar) in the body.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 4
The newer antipsychotic medications risperidone and olanzapine effectively treat schizophrenia and related disorders, and they may cause fewer side effects than the older antipsychotic drugs do. However, some of the newer antipsychotic medications could have a negative effect on the regulation of blood glucose (sugar) in the body. This negative effect could make the patient gain weight and even develop diabetes mellitus. This randomized, double-blind study will assess and compare how risperidone and olanzapine affect the regulation of glucose in the body in patients with schizophrenia and schizoaffective disorder. Patients will be randomly assigned to receive risperidone (target oral dose of 6 milligrams per day) or olanzapine (target oral dose of 20 milligrams per day) for 6 months. Repeat laboratory measurements will be performed and questions will be asked of the patients to evaluate the safety and effectiveness of the drugs. The primary laboratory test used to assess the patient's regulation of blood glucose will be the Disposition Index derived from the Frequently Sampled Intravenous Glucose Tolerance Test. Risperidone 2 milligram oven-encapsulated tablets taken orally once a day for 6 months; olanzapine 5 milligram tablets taken orally once a day for 6 months
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Target oral dose of 20 milligrams per day for 6 months
Target oral dose of 6 milligrams per day for for 6 months
Time frame: Up to 6 months
Time frame: Up to 6 months
Janssen, LP
Industry
A Six-month, Double-blind, Randomized, International, Multicenter Trial to Evaluate the Glucoregulatory Effects of Risperidone and Olanzapine in Subjects With Schizophrenia or Schizoaffective Disorder
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03847753
Acquired Immunodeficiency Syndrome, Allergy
View Trial DetailsNCT00253240
Diabetes Mellitus, Endocrine System Diseases
London, Ontario, Canada
View Trial DetailsNCT00377117
Diabetes Mellitus, Endocrine System Diseases
London, Ontario, Canada
View Trial DetailsNCT01410357
Behavior, Behavioral Symptoms
Cleveland, Ohio, United States
View Trial Details